4-Drug Combo Helps Pancreatic Cancer Patients Live Longer

A study finds a rare sign of progress in attempts to curb the tough-to-treat disease

woman in scarf receiving chemo
A chemotherapy treatment known as folfirinox is showing promising results in patients with pancreatic cancer.
Getty Images

Patients with pancreatic cancer that hadn't spread lived substantially longer on a four-drug combo than on a single standard cancer drug, a rare advance against a tough-to-treat disease, researchers reported Monday.

The results indicate the powerful chemotherapy treatment known as  folfirinox  will likely become standard of care for the minority of patients whose pancreatic cancer is diagnosed early enough to be removed by surgery, experts not involved in the study said.

More Ways to Benefit

After an average three years of follow-up, almost 40 percent of the  folfirinox  patients were disease-free, compared with about 20 percent who had the standard drug, Gemzar. Overall, almost two-thirds of  folfirinox  patients were still alive, compared with almost half of Gemzar patients, unexpectedly good results, said Thierry Conroy, the lead author and a cancer specialist at the Cancer Institute of Lorraine in Vandoeuvre- les -Nancy, France.

Results were presented Monday at an American Society of Clinical Oncology conference in Chicago. Richard Schilsky, the group's chief medical officer, called the research an "immediately practice-changing study" and said it's the biggest advance against pancreatic cancer in 25 years.

Folfirinox is already  standard  treatment for patients whose pancreatic cancer has spread.

The outlook has been bleak for patients with pancreatic cancer, an uncommon disease for which there is no screening. Symptoms including fatigue, weight loss  and  abdomen pain often don't occur until late, after the disease has spread.

About 330,000 cases are diagnosed each year worldwide, including about 55,000 in the United States. About half are diagnosed after the disease has spread; most die within a year of diagnosis, and only about 6 percent survive for five years.



AARP NEWSLETTERS

Mujer leyendo tableta

%{ newsLetterPromoText  }%

%{ description }%

Recommended For You

Unlock Access to AARP Members Edition